HIV infection
Conditions
Interventions
Sponsors
Nanning Fourth People's Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 99 Years
Inclusion criteria
Inclusion criteria: (1) Aged =50 years (2) Diagnosed HIV-1 infection, previously treated with ARVs for more than 12 months and have had at least one HIV RNA <50 copies/ml in the last six months (3) Elevated or borderline elevated lipids in at least one of the four lipid profiles following Initiation of Antiretroviral Therapy (4) The researchers judged that swith to ANV/3TC/TDF therapy was suitable (5) Understand and comply with the requirements of the study protocol and voluntarily sign a written informed consent form.
Exclusion criteria
Exclusion criteria: (1) Presence of resistance mutations to non-nucleoside drugs, lamivudine and tenofovir (2) History of NNRTI failure or switch to another regimen (3) any severe chronic disease, metabolic disease, cardiovascular disease (4) Suffering from major mental illnesses such as schizophrenia, epilepsy, severe depression/anxiety, etc; (5). During the acute infection period of HIV-1 or currently suffering from AIDS related diseases; (6). Alanine aminotransferase or aspartate aminotransferase>5 * ULN; (7) History of diagnosis of osteoporosis or osteopenia (8))Hemoglobin (Hb) =10 g/dL for males and =9 g/dL for females (9) Creatinine =1.5×ULN or glomerular filtration rate (GFR) calculated according to CKD-EPI creatinine formula =60 (ml/minute/1.73 m2) (10) Participants who have participated in clinical trials of other drugs or therapeutic devices within 30 days prior to enrollment in this study (11) Systemic immunosuppressive therapy or immunomodulatory agents were used within 30 days prior to treatment in this study, or users could not be avoided during the clinical trial (12) Participants who were able to conceive and were unable to use contraception while taking the study medication (approximately 48 weeks) and for 8 weeks after the study ended Any condition that the investigator believes may compromise the safety of the subject and affect adherence to the
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tetrapolipidemia; | — |
Secondary
| Measure | Time frame |
|---|---|
| HIV RNA <50 copies/ml ;CD4+, CD4+/CD8+; | — |
Countries
China
Contacts
Public ContactYanfen Liu
Nanning Fourth People's Hospital
Outcome results
None listed